Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) Director James Tananbaum purchased 140,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Latigo Biotherapeutics Trading Up 1.7%
LTGO stock traded up $0.31 during trading on Monday, reaching $18.56. 598,445 shares of the company were exchanged. Latigo Biotherapeutics, Inc. has a twelve month low of $17.22 and a twelve month high of $22.47.
Featured Articles
- Five stocks we like better than Latigo Biotherapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
